Not yet recruiting NCT06935968

Effect of Levonorgestrel Intrauterine System on Hemoglobin Level

No phase Interventional Hemoglobin; Deficiency

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: Levonorgestrel intrautrine system.
Who it may be relevant to: Registry conditions: Hemoglobin; Deficiency. Basic parameters: 18 years — 45 years · Female.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Official title

Effect of Levonorgestrel Intrautrine System on Hemoglobin Level and Iron Profile on Women Requiring Contraception

To study the effect of LNG-IUS on improving iron status in reproductive-aged women presenting for contraception.

Detailed description

Women come to family planning clinic to insert levonorgestrel intrautrine system and take a blood sample from her to analyse hemoglobin level

Device Levonorgestrel intrautrine system
Insertion of levonorgestrel intrautrine system and take a blood sample from the women to analyse it

Change of blood haemoglobin level from time of insertion to 6 months after insertion [Time frame: 6 months]

Secondary outcome measures (1)

Change of serum ferritin level from time of insertion to 6 months after insertionPrevalence of iron deficiency and iron deficiency anemia in women requiring contraception in our community [Time frame: 6 months]

The study will include married women attending the outpatient clinics of the forementioned health facilities for contraception counseling
Age between 18 and 45 years
Women who choose LNG\_IUS for contraception
Any parity including nulliparous

1.Women with any inherited hemoglobinopathy (thalassemia, sickle cell anemia) or acquired hemolytic anemia 2.Women with sever iron deficiency anemia requiring immediate treatment 3.Women with any contraindication to Mirena insertion (pelvic inflammatory disease, cervical or vaginal infection, cervical cancer) 4. Any uterine abnormality making LNG\_IUS insertion difficult (septate uterus or fibroid distorting the cavity) 5. Women within 6 months of delivery

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Center list to be confirmed — check the primary protocol.

NCT: NCT06935968 · Mirena